MC

576.4

0%↓

SANES

6.31

+0.72%↑

BNP

76.67

-1.3%↓

CS.FR

40.33

+1.54%↑

ALV

356.4

+0.65%↑

MC

576.4

0%↓

SANES

6.31

+0.72%↑

BNP

76.67

-1.3%↓

CS.FR

40.33

+1.54%↑

ALV

356.4

+0.65%↑

MC

576.4

0%↓

SANES

6.31

+0.72%↑

BNP

76.67

-1.3%↓

CS.FR

40.33

+1.54%↑

ALV

356.4

+0.65%↑

MC

576.4

0%↓

SANES

6.31

+0.72%↑

BNP

76.67

-1.3%↓

CS.FR

40.33

+1.54%↑

ALV

356.4

+0.65%↑

MC

576.4

0%↓

SANES

6.31

+0.72%↑

BNP

76.67

-1.3%↓

CS.FR

40.33

+1.54%↑

ALV

356.4

+0.65%↑

Search

Grifols SA

Atidarymo kaina

SektoriusFinansų sektorius

9.292 12.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.06

Max

9.168

Pagrindiniai rodikliai

By Trading Economics

Pajamos

17M

69M

Pardavimai

183M

2B

P/E

Sektoriaus vid.

45.229

22.015

Pelnas, tenkantis vienai akcijai

0.101

Pelno marža

3.491

Darbuotojai

23,833

EBITDA

57M

482M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+70.98% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.3B

6.8B

Ankstesnė atidarymo kaina

-2.74

Ankstesnė uždarymo kaina

9.292

Naujienos nuotaikos

By Acuity

35%

65%

130 / 542 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Grifols SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-07-08 10:40; UTC

Įsigijimai, susijungimai, perėmimai

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

2024-07-08 09:13; UTC

Įsigijimai, susijungimai, perėmimai

Grifols Faces Delisting Bid From Founding Family and Brookfield

Akcijų palyginimas

Kainos pokytis

Grifols SA Prognozė

Kainos tikslas

By TipRanks

70.98% į viršų

12 mėnesių prognozė

Vidutinis 14.02 EUR  70.98%

Aukščiausias 19.05 EUR

Žemiausias 11 EUR

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Grifols SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 8.574Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

130 / 542 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.